S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model.
Miyajima N, Ragab Eissa I, Abdelmoneim M, Naoe Y, Ichinose T, Matsumura S, Bustos-Villalobos I, Mukoyama N, Morimoto D, Shibata M, Takeuchi D, Tsunoda N, Kikumori T, Tanaka M, Kodera Y, Kasuya H.
Miyajima N, et al. Among authors: abdelmoneim m.
Nagoya J Med Sci. 2021 Nov;83(4):683-696. doi: 10.18999/nagjms.83.4.683.
Nagoya J Med Sci. 2021.
PMID: 34916713
Free PMC article.